GAMT Deficiency: Clinical Presentation, Treatment, Diagnosis, Animal Models, Preclinical and Clinical Developments

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Guanidinoacetate Methyl Transferase (GAMT) deficiency is a rare genetic disorder.
• It leads to neurodevelopmental derangements, epilepsy, and movement disorders.
• Pathophysiology involves postnatal brain creatine depletion and guanidinoacetate toxicity.

Purpose of the Study:

• To review current therapeutic strategies for GAMT deficiency.
• To summarize preclinical investigations for novel treatments.
• To discuss diagnostic methods and animal models for GAMT deficiency.

Main Methods:

• Literature review of current and emerging treatments for GAMT deficiency.
• Summary of preclinical research on enzyme restoration therapies.
• Description of diagnostic approaches and available animal models.

Main Results:

• Current treatments (creatine supplementation, metabolic management) partially mitigate GAMT deficiency but don't normalize metabolites.
• Preclinical studies are investigating enzyme restoration as a potential cure.
• Established mouse models aid in understanding disease mechanisms and testing therapies.

Conclusions:

• GAMT deficiency requires comprehensive management, including early diagnosis and current therapies.
• Emerging preclinical research offers hope for more effective treatments, potentially targeting enzyme restoration.
• Animal models are crucial for advancing research and therapeutic development for this ultrarare condition.